Skip to Main Content
Contribute Try STAT+ Today

Last week, the genome-editing scientists behind base editing, a technology dubbed CRISPR 2.0, gathered for an update from the competition. Intellia Therapeutics, a company invested in the classic form of CRISPR, was to unveil its take on base editing, a refined approach to fixing DNA that corrects single letters of the genome without breaking the double helix.

The presentation, hosted by the famed Cold Spring Harbor Laboratory, sounded familiar.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!


What is it?

STAT+ is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.